Press release - 20/10/2020 EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/eib-backs-atriva-therapeutics-eur24-million-development-potential-covid-19-treatment
Article - 29/07/2008 Frank Kirchhoff advances AIDS research by posing the right questions Frank Kirchhoff an AIDS researcher from Ulm has learnt to pose important questions and find the right answers during his post-graduate studies. This recipe has brought him and his research group international recognition and makes him one of the best AIDS researchers worldwide. Important publications within a very short time and numerous awards are clear evidence of his outstanding achievements. In addition he has just started a clinical trial…https:////www.gesundheitsindustrie-bw.de/en/article/news/frank-kirchhoff-advances-aids-research-by-posing-the-right-questions
Press release - 03/03/2020 CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force Daniel Menichella, CEO of biopharmaceutical company CureVac, was today invited to the White House to discuss strategies and opportunities for the rapid development and production of a coronavirus vaccine with U.S. President Donald Trump, Vice President Mike Pence, members of the White House Coronavirus Task Force and high-ranking representatives of pharmaceutical and biotech companies working on the outbreak’s response. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-CEO-Daniel-Menichella-Discusses-Coronavirus-Vaccine-Development-with-U-S-President-Donald-Trump-and-Members-of-Coronavir
Article - 13/09/2016 Catalent – galenics experts from Schorndorf Pharmaceutical and biotechnology companies are working intensively on the discovery and development of new drugs for the efficient and safe treatment of diseases. However, before drugs are authorised for treating humans and animals, they have to be made into a form that is acceptable. That is where a company called Catalent Pharma Solutions, with a facility in Schorndorf in the south of Germany, comes in.https:////www.gesundheitsindustrie-bw.de/en/article/news/catalent-galenics-experts-from-schorndorf
Article - 09/02/2015 Joining forces to develop anti-cancer immunotherapies No cancer therapy is currently achieving such promising results as immunotherapy. The German Cancer Research Center and Bayer HealthCare have established a joint laboratory to develop novel immunotherapies that selectively reactivate the body’s own immune system and incite it to attack tumour cells, thereby supporting the faster translation of concepts from the laboratory into clinical application.https:////www.gesundheitsindustrie-bw.de/en/article/news/joining-forces-to-develop-anti-cancer-immunotherapies
Press release - 30/10/2012 DKFZ and Genetic Immunity Sign Collaboration Agreement to Develop HPV Therapeutic Vaccine Genetic Immunity, Budapest, a leader in immunotherapy technology product development, and DKFZ (German Cancer Research Center, Heidelberg, Germany) signed a collaborative agreement to develop a DNA-based vaccine for the treatment of Human Papilloma Virus (HPV) infection that causes cervical cancer and other cancers of the anus, penis, vulva, vagina, and oropharynx. Present HPV vaccines (Cervarix, Gardasil) have no therapeutic effect on…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-and-genetic-immunity-sign-collaboration-agreement-to-develop-hpv-therapeutic-vaccine
Retrospective Meet & Match Pharmaceutical Process Technology - 07/04/2016 Speed dating for Pharmaceutical Process Technology – a business flirt at Bosch The speed dating format is no longer just a popular and simple dating method for lonely hearts, but has also become a rewarding way for establishing new business contacts and connections quickly and efficiently. BIOPRO Baden-Württemberg chose speed networking, as speed dating is called in the corporate world, for its recent Meet & Match event on pharmaceutical process technology, which took place on 15th March 2016 with the support of Bosch…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/speed-dating-for-pharmaceutical-process-technology-a-business-flirt-at-bosch
Article - 21/08/2018 Parkinson's disease: vitamin B3 has a positive effect on nerve cells Parkinson's disease is one of the most common neurodegenerative diseases in the world. There are around 4.1 million sufferers worldwide. It is characterised by motor impairments that result from the death of certain nerve cells in the brain. Researchers at the University of Tübingen have now discovered that vitamin B3 has a positive effect on damaged nerve cells and can boost their energy metabolism.https:////www.gesundheitsindustrie-bw.de/en/article/news/parkinsons-disease-vitamin-b3-has-a-positive-effect-on-nerve-cells
Big Data - 14/12/2017 Looking at the whole genome raises new questions Research laboratories around the world have long focused on studying the whole human genome. It is hoped that knowing the whole human genome will improve diagnostics and enable more specific therapies. Although genome analysis has not yet reached routine clinical application, whole genome sequencing has already raised many ethical and legal issues - for researchers, physicians and patients.https:////www.gesundheitsindustrie-bw.de/en/article/news/looking-at-the-whole-genome-raises-new-questions
Press release - 06/04/2017 Start-up in the garage – a location with prospects Newly established start-up wins award – Mireca Medicines GmbH develops treatment for hereditary eye disease and receives Innovation Award of the biotechnology regions in Germanyhttps:////www.gesundheitsindustrie-bw.de/en/article/press-release/start-up-in-the-garage-a-location-with-prospects
Alternative to animal experiments - 21/03/2018 Drug tests using miniature organs At present, potential new drugs have to be tested on animals before they can be used on humans. However, results obtained from animals are not always transferrable to the situation in humans, which is why researchers around the world have long been seeking alternatives. Miniature human organs that can be used to test the efficacy of potential human drugs might provide a solution.https:////www.gesundheitsindustrie-bw.de/en/article/news/drug-tests-using-miniature-organs
Article - 23/05/2018 Bacteriophages as alternatives to antibiotics Multidrug-resistant bacteria are resistant to many existing antibiotics and can be difficult to treat. There are increasing numbers of them worldwide. Although novel antibiotics are being developed, there are far too few of them to tackle the rise of multidrug-resistant bacteria. In Eastern Europe, doctors have been treating bacterial infections with viruses that infect bacteria, so-called bacteriophages, for almost 100 years.https:////www.gesundheitsindustrie-bw.de/en/article/news/bacteriophages-as-alternatives-to-antibiotics
Press release - 04/10/2017 Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies Tuebingen, Germany and Houston, Texas, October 4, 2017 – Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-receives-58-million-in-financing-to-develop-t-cell-receptor-based-immunotherapies
Big Data - 13/03/2018 “More data does not automatically imply more knowledge“ In Germany, one of the big names in evidence-based medicine is Prof. Dr. rer. nat. Gerd Antes, co-director of Cochrane Germany. In the following interview, Antes talks about the hype surrounding big data, warns against false promises and reminds us about what is taken for granted. https:////www.gesundheitsindustrie-bw.de/en/article/news/more-data-does-not-automatically-imply-more-knowledge
Press release - 19/10/2009 New ulcerative colitis therapy in sight Lipid Therapeutics GmbH and Dr. Falk Pharma GmbH announced on 30th, September, that they have entered into a co-development and licensing agreement for LT-02. Under the terms of the agreement, Dr. Falk Pharma will receive exclusive access to the European rights to Lipid Therapeutics’ lead product LT-02 for the treatment of ulcerative colitis. Ulcerative colitis is a severe inflammation of the colon affecting more than one million people…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/new-ulcerative-colitis-therapy-in-sight
Article - 20/10/2014 First ever eye gene therapy close to clinical testing There are many different retinal diseases simply because many different steps of the visual process can be affected. However, they all have one thing in common: correction of the relevant defective gene currently provides the only possibility of permanent cure. Prof. Dr. Mathias Seeliger and his group of researchers at the Institute of Ophthalmic Research at the University Hospital in Tübingen is specifically focused on the development of gene…https:////www.gesundheitsindustrie-bw.de/en/article/news/first-ever-eye-gene-therapy-close-to-clinical-testing
Press release - 19/05/2011 Curetis AG successfully increases Series A financing round to EUR 24.5 million Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced an extension of its Series A financing, bringing the total size of the round to € 24.5 million. CD-Venture joined the funding as a new investor, while all of Curetis' existing VC investors participated in the round. Several private investors also continued to…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-successfully-increases-series-a-financing-round-to-eur-24-5-million
Article - 16/06/2014 Methadone – the last step to becoming an anti-cancer drug It all began several years ago with a surprising discovery in the laboratory. Claudia Friesen, a chemist at Ulm University, discovered that leukaemia cells that were exposed to methadone died within a relatively short period of time. Seven years on and many papers later, what was once a rather exotic substance is now undergoing clinical testing in cancer patients.https:////www.gesundheitsindustrie-bw.de/en/article/news/methadone-the-last-step-to-becoming-an-anti-cancer-drug
Press release - 12/08/2010 Glycotope Received Regulatory Approval for Glycooptimized and Fully Human Glycosylated Antibody CetuGEX™ and Enrolls First Patients in Clinical Trial Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX™ (GT-MAB 5.2-GEX) for the treatment of various solid cancers. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/glycotope-received-regulatory-approval-for-glycooptimized-and-fully-human-glycosylated-antibody-cetu
Press release - 07/10/2020 Joining forces against SARS-CoV-2 Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/joining-forces-against-sars-cov-2
Press release - 13/11/2009 Single molecules under the laser: How the genetic material is unwrapped The genetic material found in cells is not in its free state, but is bound to large protein complexes and tightly wrapped. To activate genes that could well play a role in carcinogenesis, the genetic material first needs to be unwrapped and made accessible to other cell components. Using a new biophysical method called single molecule spectroscopy, scientists from the “Biophysics of Macromolecules” division at the German Cancer Research Centre…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/single-molecules-under-the-laser-how-the-genetic-material-is-unwrapped
Article - 22/02/2017 Review: New European directives will impact the medical technology industry The new Medical Device Regulation (MDR) and the first In Vitro Diagnostic Devices Regulation (IVDR) are likely to become European law in the second half of 2017, with transitional periods of three and five years, respectively. https:////www.gesundheitsindustrie-bw.de/en/article/news/review-new-european-directives-will-impact-the-medical-technology-industry
Press release - 14/07/2016 Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines CureVac AG, the most clinically advanced mRNA company, today announced that a study of its RNActive® technology was published in the renowned, peer-reviewed journal Vaccine. The study demonstrated a mechanistic insight into the mode of action and rationale for the use of messenger RNA (mRNA) for the development of multiple vaccines.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/study-in-peer-reviewed-journal-vaccine-demonstrates-decoding-mode-of-action-of-mrna-vaccines
Press release - 05/11/2014 Orphan drug status for Synovo's immune modulator SYD003 The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to Synovo's investigational compound SYD003, a first in class tumour-targeted immune modulator.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/orphan-drug-status-for-synovo-s-immune-modulator-syd003
Personalised Medicine - 04/05/2017 Big data make therapy work better An international team of researchers has shown for acute myeloid leukaemia (AML) that cancer therapy can be personalised using big data. The authors of the study “believe this paper is a step towards validation of genetic techniques as a route to personalised medicine”. https:////www.gesundheitsindustrie-bw.de/en/article/news/mit-big-data-genauer-therapieren